Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 20, 2017
Pharmacy Choice - News - Generic Drugs - October 20, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 61     Next >>     Go To Page:

10/20/17 - Adverse events spike after blood pressure meds go generic in Canada
By a News Reporter-Staff News Editor at Drug Week DALLAS, One month after generic versions of three widely-used blood pressure drugs became available in Canada, hospital visits for adverse events spiked in generic drug users, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
10/20/17 - Alvogen Obtains First Approval for Glatiramer Acetate 40 mg/mL in Europe
The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the US, Romania, Korea and Taiwan. North America is Alvogen's single largest market and other key markets include: South Korea, Russia, Hungary, Romania, Taiwan, Ukraine, Japan and China. A consortium of investors, led
10/20/17 - Developing Treatments for Blindness in Children: The Role of the Paediatric Medicines Regulation (PMR)
The European Federation of Pharmaceutical Industries and Associations issued the following news release:. With over 7000 medicines in development, new treatments will continue to change patients' lives; slowing disease progression, avoiding illness and reducing overall costs for healthcare systems. But developing a new medicines is a long, complex
10/20/17 - Dr. Reddy's Laboratories Announces the Launch of Sevelamer Carbonate Tablets in the U.S. Market
By a News Reporter-Staff News Editor at Drug Week Dr. Reddy's Laboratories Ltd. announced that it has launched Sevelamer Carbonate Tablets, 800 mg, a therapeutic equivalent generic version of Renvela Tablets, approved by the U.S. Food and Drug Administration. "We are very pleased to bring Sevelamer Carbonate Tablets to market at this time," s
10/20/17 - Findings from Pfizer Provides New Data on Biosimilars (Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis)
According to news reporting originating from New York City, New York, by NewsRx correspondents, research stated, "Biosimilar drugs are highly similar to an originator biologic, with no clinically meaningful differences in terms of safety or efficacy. Financial support for this research came from Pfizer. Our news editors obtained a quote from the re
10/20/17 - Industry asks govt not to cap margins on unbranded generics [Arab News (Saudi Arabia)]
In a latest submission, the industry told the Department of Pharmaceuticals that total margin of 35 per cent on branded drugs is an ideal number, said a senior official from the department. The government began thinking about capping trade margin of drugs in 2015 after the Maharasthra Food and Drug Administration raised a complaint against a cough
10/20/17 - Novartis AG (ADR)(NYSE:NVS) To Shut Down Sandoz Generic Facility In Denver
Swiss pharmaceutical giant Novartis AG (ADR)(NYSE:NVS) has announced that it will lay off 450 workers in the U.S. in the course of the next two years as it moves to gradually close down its generics manufacturing facility which is located in the state of Colorado. This comes at a time when the drugmaker is facing [?] The post Novartis AG (ADR)(NY
10/20/17 - The Future of the $12 Billion U.S. Biologics and Biosimilars Treatment Market for Psoriasis to 2021
The "The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis" report has been added to Research and Markets' offering. The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6 bn in 2016 is projected to almost double during the forecast period to reach $12.9 bn in 2021 driven by safety and effi
10/20/17 - United States Biologics and Biosimilars Treatment Market 2017-2021
The "The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis" report has been added to Research and Markets' offering.. Major Takeaways The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6 bn in 2016 is projected to almost double during the forecast period to reach $12.9 bn in 2021 driven
10/19/17 - Abzena and UGA Biopharma Partner to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple Sclerosis
CAMBRIDGE, England& HENNIGSDORF, Germany Abzena plc, the life sciences group providing integrated solutions and technologies enabling the development and manufacture of biopharmaceutical products, and UGA Biopharma GmbH, a cell line development specialist, announce the completion of the development of a biosimilar cell line to treat Multiple Sc
10/19/17 - Aurobindo Pharma receives USFDA Approval for Esomeprazole Magnesium DR Capsules OTC
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food& Drug Administration to manufacture Esomeprazole Magnesium Delayed-Release Capsules OTC, 20 mg. Aurobindo Pharma Limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.
10/19/17 - Breakfast Technical Briefing on Biotech Stocks Coherus Biosciences, Exelixis, Geron, and Grifols
Investor's Business Daily reported that 35 years after the first FDA- approved biotech drug, the Biotech industry is rolling out innovations at a breakneck pace. In today's pre-market research, redirects investors' attention to the performance of the following equities: Coherus Biosciences Inc., Exelixis Inc., Geron Corp., and
10/19/17 - Claire McCaskill's crusade could hurt Native American rights
It has been asked throughout history: Haven't Native American tribes suffered enough? In September, the drug maker Allergan gave six patents for the drug Restasis to the upstate New York- based Saint Regis Mohawk Tribe, and paid the tribe $13.5 million to accept the patents and grant an exclusive license, also promising $15 million annually until t
10/19/17 - Corporate News Blog - Impax Labs to Merge with Amneal Pharma Through an All-stock Transaction
LONDON, UK/ ACCESSWIRE/ October 19, 2017/ Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Impax Laboratories, Inc., following which we have published a free report that can be viewed by signing up at Impax and Amneal Pharmaceuticals LLC, one of the largest and fastest
10/19/17 - FTC Announces Agenda for November 8 Workshop on Examining Competition Issues Related to Prescription Drug Markets
The Federal Trade Commission issued the following news release:. The workshop, titled "Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics," will take place on November 8, 2017 at the FTC's Constitution Center Auditorium, 400 7th St., SW, Washington, DC. Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and
10/19/17 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 46065) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a workshop titled "Topical Dermatological Generic Drug Products: Overcoming Barriers to Development and Improving Patient Access," to provide an overview of current regulatory science initiatives related to generic topical dermatological drug products.
10/19/17 - Interview with Pfenex Explores Market Access and Pricing of Biosimilars in North America
SMi Group has announced that Mr Patrick Lucy, CEO of Pfenex, has joined the speaker line-up for the 4th annual Biosimilars North America conference which takes place on November 15& 16 in New Jersey. In the run-up to the conference, SMi Group had a quickfire interview with Patrick Lucy. He will also share some top tips on what to keep in mind mov
10/19/17 - Nexus Pharmaceuticals Receives FDA Approval for Procainamide HCL Injection, USP
Nexus Pharmaceuticals announced today the immediate availability in the United States of Procainamide HCL Injection, USP. "The introduction of Procainamide HCL Injection, USP further illustrates Nexus Pharmaceuticals' commitment to meeting market needs and shortages in the short term, while broadening the availability of effective generic produc
10/19/17 - Novum Selects OmniComm as Strategic EDC Partner
Novum Pharmaceutical Research Services, a leading U.S. contract research organization, has selected TrialMaster electronic data capture technology from OmniComm Systems, Inc.,, a leading global provider of clinical data management technology. Founded in 1972, the Pittsburgh- based CRO conducts Phase I to Phase IV complex generic and new drug clin
10/18/17 - Federal Register Table of Contents
Table of Contents Office of the Federal Register Agriculture Department SeeGrain Inspection, Packers and Stockyards Administration SeeRural Utilities Service NOTICES Agency Information Collection Activities; Proposals, Submissions, and Approvals: Fast Track Generic Clearance for Collection of Qualitative Feedback on Customer Satisfaction...
10/18/17 - Generic Drugs Stocks on Investors' Radar pSivida, Tetraphase Pharma, Catalent, and Lannett
This Wednesday morning, looks at the performance of these four Drugs- Generic stocks: pSivida Corp., Tetraphase Pharmaceuticals Inc., Catalent Inc., and Lannett Co. Inc.. On Tuesday, shares in Watertown, Massachusetts headquartered pSivida Corp. recorded a trading volume of 671,482 shares, which was above their three months av
10/18/17 - Glenmark gets US FDA nod for generic of Emend capsules [Algeria Press Service]
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food& Drug Administration for Aprepitant Capsules USP, 40 mg, 80 mg, and 125 mg, the generic version of Emend Capsules, 40 mg, 80 mg, and 125 mg, of Merck Sharp& Dohme Corporation. According to IMS Health sales data for the 12 month period ending August 2017, th
10/18/17 - NEOS THERAPEUTICS, INC. FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
On October 17, 2017, Neos Therapeutics, Inc. entered into a confidential Settlement and Licensing Agreement with Actavis Laboratoris FL, Inc.. This Agreement resolves all ongoing litigation involving the Company's patents protecting its Adzenys XR-ODT extended-release orally disintegrating tablets and Actavis's Abbreviated New Drug Application..
10/18/17 - Specialty Generics Market Is Anticipated To Grow Rapidly Due To Rise In Prevalence Of Chronic Diseases Till 2025: Grand View Research, Inc.
According to report published by Grand View Research, The Global Specialty Generics Market size was estimated at USD 30.0 billion in 2016. The Global Specialty Generics Market is expected to reach USD 174.9 billion by 2025, according to a new report by Grand View Research, Inc. Rise in demand for low-cost generic specialty drugs is a major factor e
10/18/17 - The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis
The new report from MP Advisors titled "The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis" examines in detail the current treatment landscape and the outlook through 2021 of psoriasis treatment market facing the U.S. Biologics and the Biosimilars. The report is authored by a seasoned Analyst with experience of over 15
Articles(s): 1 - 25 of 61     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement